Catalyst Pharmaceuticals, Inc. (CPRX) Stock Score, Valuation & Financial Research
Catalyst Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 69/100.
Quick answer for CPRX
Catalyst Pharmaceuticals, Inc. currently has a Wall Street Score of 69/100. The stored market price is $31.49. Its financial score is 55/100. Its valuation score is 93/100. These figures are a research snapshot, not a buy or sell recommendation.
What Catalyst Pharmaceuticals, Inc. does
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. T
CPRX financial snapshot
- Wall Street Score:
- 69/100
- Current price:
- $31.49
- Market capitalization:
- $3.85B
- Revenue:
- $597.0M
- Net income:
- $221.3M
- Free cash flow:
- $208.6M
- Cash:
- $755.9M
- Total debt:
- $2.7M
- EPS:
- 1.80
- P/E ratio:
- 17.5x
- Financial score:
- 55/100
- Valuation score:
- 93/100
- Revenue score:
- 41/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $208.6M, showing positive cash generation.
- The balance sheet shows $755.9M of cash versus $2.7M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 93/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 55/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CPRX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.